AGEN (Agenus Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by AGEN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-08-11 | Brian Corvese | Director | A | — | — |
| 2026-08-11 | THOMAS L HARRISON | Director | A | — | — |
| 2026-08-07 | Timothy Wright | Director | A | — | — |
| 2026-08-07 | Steven J O'Day | Chief Medical Officer | A | — | — |
| 2026-08-07 | Jennifer Buell | See Remarks | A | — | — |
| 2026-08-07 | Susan B Hirsch | Director | A | — | — |
| 2026-08-07 | Jennifer Buell | See Remarks | A | — | — |
| 2026-08-07 | Timothy Wright | Director | A | — | — |
| 2026-08-07 | Steven J O'Day | Chief Medical Officer | A | — | — |
| 2026-08-07 | Susan B Hirsch | Director | A | — | — |
| 2026-07-14 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-07-07 | THOMAS L HARRISON | Director | A | — | — |
| 2026-07-07 | Timothy Wright | Director | A | — | — |
| 2026-06-16 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-06-02 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-05-19 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-05-05 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-04-28 | Steven J O'Day | Chief Medical Officer | A | — | — |
| 2026-04-28 | THOMAS L HARRISON | Director | A | — | — |
| 2026-04-28 | Jennifer Buell | See Remarks | A | — | — |
| 2026-04-28 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-04-28 | Susan B Hirsch | Director | A | — | — |
| 2026-04-28 | Timothy Wright | Director | A | — | — |
| 2026-04-28 | Austin Charette | Principal Accounting Officer | A | — | — |
| 2026-04-28 | Brian Corvese | Director | A | — | — |
| 2026-04-21 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-04-13 | THOMAS L HARRISON | Director | A | — | — |
| 2026-04-06 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-04-02 | Timothy Wright | Director | A | — | — |
| 2026-03-24 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-03-09 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-02-24 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-02-09 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-01-26 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-01-12 | GARO H ARMEN | See Remarks | A | — | — |
| 2026-01-05 | THOMAS L HARRISON | Director | A | — | — |
| 2026-01-05 | Timothy Wright | Director | A | — | — |
| 2025-12-29 | GARO H ARMEN | See Remarks | A | — | — |
| 2025-12-15 | GARO H ARMEN | See Remarks | A | — | — |
| 2025-12-01 | GARO H ARMEN | See Remarks | A | — | — |
| 2025-11-17 | GARO H ARMEN | See Remarks | A | — | — |
| 2025-11-05 | GARO H ARMEN | See Remarks | A | — | — |
| 2025-10-21 | GARO H ARMEN | See Remarks | A | — | — |
| 2025-10-06 | GARO H ARMEN | See Remarks | A | — | — |
| 2025-10-03 | Timothy Wright | Director | A | — | — |
| 2025-10-03 | THOMAS L HARRISON | Director | A | — | — |
| 2025-09-23 | GARO H ARMEN | See Remarks | A | — | — |
| 2025-09-09 | GARO H ARMEN | See Remarks | A | — | — |
| 2025-08-26 | GARO H ARMEN | See Remarks | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 855,744 | — |
| — | See Remarks | 402,406 | — |
| — | 10%+ Owner | 369,018 | — |
| — | Director | 79,365 | — |
| — | Chief Medical Officer | 57,116 | — |
| — | Director | 47,545 | — |
| — | PFO & PAO | 23,480 | — |
| — | See Remarks | 19,738 | — |
| — | Director | 9,280 | — |
| — | Director | 6,203 | — |
| — | Director | 5,436 | — |
| — | Chief Legal Officer and GC | 5,076 | — |
| — | Director | 4,604 | — |
| — | Director | 3,309 | — |
| — | Chief Commercial Officer | 3,125 | — |
| — | VP, Clinical, Reg & Qual | 2,870 | — |
| — | Director | 2,520 | — |
| — | President R&D | 1,669 | — |
| — | CFO | 1,595 | — |
| — | Chief Technology Officer | 1,051 | — |
| — | Director | 959 | — |
| — | Director | 248 | — |
| — | Director | 167 | — |
| — | Director | 128 | — |
| — | Director | 13 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AGEN quote page; the site-wide leaderboard is on the insider transactions hub.